ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: SA-PO1014

Expression and Modulation of SGLT2 in Human Podocytes: Not All in Tubule

Session Information

Category: Glomerular Diseases

  • 1403 Podocyte Biology

Authors

  • Riera, Marta, Institut Hospital del Mar d'Investigacions Mediques, Barcelona, Catalunya, Spain
  • Galdón, Eric, Institut Hospital del Mar d'Investigacions Mediques, Barcelona, Catalunya, Spain
  • García, David Silva, Institut Hospital del Mar d'Investigacions Mediques, Barcelona, Catalunya, Spain
  • Fajardo, Ana Amador, Institut Hospital del Mar d'Investigacions Mediques, Barcelona, Catalunya, Spain
  • Milan, Cristina Cervera, Institut Hospital del Mar d'Investigacions Mediques, Barcelona, Catalunya, Spain
  • Rosco, Claudia Martyn, Institut Hospital del Mar d'Investigacions Mediques, Barcelona, Catalunya, Spain
  • Rodriguez, Eva, Hospital del Mar, Barcelona, Catalunya, Spain
  • Crespo, Marta, Hospital del Mar, Barcelona, Catalunya, Spain
  • Barrios, Clara, Institut Hospital del Mar d'Investigacions Mediques, Barcelona, Catalunya, Spain

Group or Team Name

  • GREN.
Background

Inhibitors of the sodium-glucose cotransporter type 2 (iSGLT2) modify important non-glycemic pathways that lead to the protection of target organs. Its renoprotective pleiotropic effects in CKD, associated or not with diabetes, justifies further studies to elucidate the mechanisms of action (MoA) of these drugs. Although the co-transporter is mostly expressed in the proximal tubule, its location and function in other cells, potential therapeutic targets for inhibitor drugs, has not been well studied. We explored the presence of SGLT2 in human podocyte cells and whether it is modified in different situations of cellular stress.

Methods

Differentiated immortalized human podocytes were cultured under different experimental conditions for 24 or 48 h: Normoxia (Control); Normoxia + High concentration of glucose (HG); Hypoxia+2h Reoxygenation(H) and the combination H+HG. We also incubated with 0.1uM Dihydrotestosterone (DHT). SGLT2 gene expression was determined by quantitative PCR and SGLT2 protein was detected by Western Blot (WB) and immunofluorescence (IF).

Results

Sglt2 gene expression was detected with an increase after 24h of exposure to HG. Protein expression by WB showed a non-significant increase after 48h of exposure to HG and hypoxia, which was significant with co-incubation with DHT. The IF measured by intensity of area did not show an increase in the protein expression of the transporter under HG incubation. However, protein expression increased under all hypoxia conditions: Control 50.05±3, Hypoxia 140±16.3 (p<0.05 vs control) and HG+Hypoxia 253±21.29 (p<0.001 vs control).

Conclusion

Our data suggest that podocyte may be one of the therapeutic targets on which the iSGLT2 are acting . The experimental conditions described did not show differences in the expression of the transporter before the single stimulus of glucose, but they did under hypoxia and the combination Hypoxia-high glucose. In addition, co-incubation with testosterone seems to enhance the expression. Studying the MoA of iSGLT2 will open better comprehension of the kidney pathophysiology, particularly in the podocytopathies, regardless of diabetes.